<DOC>
	<DOCNO>NCT02962778</DOCNO>
	<brief_summary>This study evaluate RAS peptide profile patient treatment resistant arterial hypertension .</brief_summary>
	<brief_title>RAS Peptide Profiles Patients With Treatment-resistant Arterial Hypertension</brief_title>
	<detailed_description>Selective quantification RAS peptides human plasma trigger investigation evaluate whether RAS peptide could use clinical biomarkers patient receive antihypertensive treatment . Drug-specific RAS profile first characterize healthy normotensive subject ( EKBB 255/12 ; ClinicalTrials.gov ID NCT01771783 ) presently investigate patient newly diagnose arterial hypertension ( EKNZ 2015-081 ; clinicaltrials.gov identifier ( ID ) NCT02449811 ) . With observational study RAS peptide profile characterize patient treatment resistant hypertension . Data generate study show whether RAS peptide profile merit evaluation clinical biomarkers complex patient group .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<criteria>Inclusion criterion Office blood pressure ≥ 140/90 mmHg mean 24 hour blood pressure &gt; 130/80 mmHg average , &gt; 135/85 mmHg day , &gt; 120/70 mmHg night , despite concurrent use 3 antihypertensive agent optimal dos , include one diuretic OR Office blood pressure 24 hour mean blood pressure control four medication Age ≥ 18 year Ability understand research procedure provide write informed consent Exclusion criterion Known secondary arterial hypertension time inclusion diagnosis secondary hypertension study inclusion routine workup treatment resistant hypertension Known obstructive sleep apnea time inclusion History , clinically relevant uncontrolled cardiovascular disease ( arterial hypertension ) , namely myocardial infarction within last 3 month valvular heart disease clinically relevant reflux heart failure Any circumstance condition , , opinion investigator , may affect full participation research project compliance research plan .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>treatment-resistant</keyword>
</DOC>